Editorial Policy

Our content is written in-house. Sarah Miletich holds an MS in Cosmetic Science and formulates our products; Julie Mercer-Ingram is a cannabis attorney and our co-founder. Where an article touches either of their areas, they write or review it. Every article carries a named byline linking to that person's profile — we do not publish anonymously.

We cite primary sources only. That means FDA labelling and guidance, the National Institutes of Health and NCCIH, peer-reviewed literature, and the guidance of the relevant professional body — the American Veterinary Medical Association for pet content, anesthesiology societies for surgical content.

We do not cite other CBD retailers, content marketing sites, or secondary summaries of research. If we cannot find a primary source for a claim, we do not make the claim.

Every source is linked so you can check it. Every article that makes a clinical claim carries a Sources section at the end.

CBD is not approved by the FDA to diagnose, treat, cure or prevent any disease, and we do not write as though it were.

Specifically, we do not claim our products treat medical conditions; we do not present preclinical or animal research as though it were clinical evidence in people; we do not transfer findings from THC-containing research onto our THC-free products; and where the evidence is weak, we say so rather than reaching for softer language.

That last one costs us occasionally. We think it is the right trade.

Content making clinical claims — drug interactions, safety, dosing, anything touching a medical condition — is reviewed by a qualified professional before publication. Health and safety content is reviewed by a pharmacist or physician; pet content is reviewed by a veterinarian.

Reviewed articles carry the reviewer's name, credential and review date directly under the byline. If an article does not carry a reviewer line, it has not been through clinical review — and you should read it accordingly.

Guidance changes. Research is published. Laws move, and in this category they move often.

We review our safety and regulatory content at least annually, and sooner when something material changes. Every article shows a published date, and an updated date where the content has genuinely been revised — we do not bump dates to look fresh.

If we get something wrong, we fix it and we say so. Material corrections are noted at the foot of the article with the date.

If you have found an error, tell us: contact page. We would rather hear it from you than leave it up.

We sell CBD products, which is a conflict of interest and one we would rather name than leave for you to discover. Our content links to our products where they are relevant. It does not adjust its conclusions to suit them — the clearest example being our articles on migraine and on drug testing, both of which tell readers things that do not help us sell anything.